Back to Search Start Over

Review of the recent advances of pyrazole derivatives as selective COX-2 inhibitors for treating inflammation.

Authors :
Ghoneim MM
Abdelgawad MA
Elkanzi NAA
Bakr RB
Source :
Molecular diversity [Mol Divers] 2024 Jul 16. Date of Electronic Publication: 2024 Jul 16.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Pyrazole heterocycle is regarded as an extremely significant agent for the therapy of inflammation. Celecoxib, lonazolac, deracoxib, and phenylbutazone are examples of commercially approved pyrazole drugs with COX-2 inhibitory potential for curing inflammation. There have been recently many reviews for the biological significance of pyrazole derivatives. This review talks about pyrazole derivatives with anti-inflammatory activity and also sheds the light on the recent updates on pyrazole research with an emphasis on some synthetic pathways utilized to construct this privileged scaffold and structure activity relationship that accounts for the anti-inflammatory activity in an attempt to pave the opportunity for medicinal chemists to develop novel anti-inflammatory agents with better COX-2 selectivity.<br /> (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)

Details

Language :
English
ISSN :
1573-501X
Database :
MEDLINE
Journal :
Molecular diversity
Publication Type :
Academic Journal
Accession number :
39014146
Full Text :
https://doi.org/10.1007/s11030-024-10906-9